ELEVATED SERUM LEVELS OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN POLYMYOSITIS/DERMATOMYOSITIS. A Biologic Marker of Disease Activity with a Possible Role in the Lack of Acute-Phase Protein Response
Article first published online: 9 DEC 2005
Copyright © 1994 American College of Rheumatology
Arthritis & Rheumatism
Volume 37, Issue 12, pages 1744–1751, December 1994
How to Cite
Gabay, C., Gay-Croisier, F., Roux-Lombard, P., Meyer, O., Maineti, C., Guerne, P.-A., Vischer, T. and Dayer, J.-M. (1994), ELEVATED SERUM LEVELS OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN POLYMYOSITIS/DERMATOMYOSITIS. A Biologic Marker of Disease Activity with a Possible Role in the Lack of Acute-Phase Protein Response. Arthritis & Rheumatism, 37: 1744–1751. doi: 10.1002/art.1780371206
- Issue published online: 9 DEC 2005
- Article first published online: 9 DEC 2005
- Manuscript Accepted: 7 JUL 1994
- Manuscript Received: 21 MAR 1994
- Swiss National Science Foundation. Grant Number: 31-33786.92
- “Subvention fédérale pour la lutte contre le Rhumatisme.”. Grant Number: 31-30076.90
Objective. To determine whether the lack of acute-phase protein (APP) response in numerous patients with polymyositis/dermatomyositis (PM/DM) is related to an imbalance between cytokines and cytokine inhibitors.
Methods. Levels of C-reactive protein (CRP), interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), IL-6, IL-1 receptor antagonist (IL-1ra), TNF soluble receptor 55 kd (sTNFR 55 kd), and sTNFR 75 kd were tested in the serum of 15 patients with PM/DM, 14 patients with spondylarthropathies (SPA), and 12 healthy blood donors. Serum IL-1β, TNFα, IL-6, IL-1ra, sTNFR were measured by specific immunoassays.
Results. Serum levels of CRP were lower in PM/DM patients than in SPA patients. Normal or slightly elevated CRP values were found in 10 of the 15 PM/DM patients, 7 of whom had active myositis. Serum IL-6 levels were significantly higher in SPA patients than in PM/DM patients, whereas serum IL-1ra and sTNFR levels were significantly higher in PM/DM than in SPA patients. IL-1ra levels were particularly elevated in patients with active myositis and decreased in response to treatment.
Conclusion. These differences in cytokine levels, particularly IL-1ra, between PM/DM and SPA patients are indicative of distinct pathogenic mechanisms. High levels of IL-1ra may account for the weak APP response in some PM/DM patients. Our results suggest that measurement of IL-1ra, together with clinical examination, may provide useful information for the followup of PM/DM patients.